PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17280678-4 2007 Compared with PBO, RSG also significantly reduced plasminogen activator inhibitor-1 (-36.9%, P<0.001), tissue plasminogen activator antigen (-22.7%, P<0.001), FPG (-2.8 mmol/l, P<0.001), fasting fructosamine (-42.0 mg/dl, P<0.001). Rosiglitazone 19-22 serpin family E member 1 Homo sapiens 50-83 17932317-3 2007 Stepwise multiple linear regression analysis identified the reduction in plasma fasting glucose and the rise in adiponectin levels to be independently associated with the reduction in PAI-I concentration in the rosiglitazone-treated patients. Rosiglitazone 211-224 serpin family E member 1 Homo sapiens 184-187 17305652-11 2007 RSG treatment led to significant reductions of HOMA-IR, fasting plasma glucose, HbA1c, PAI-1 activity, fibrinogen, C-reactive protein and matrix metalloproteinase-9. Rosiglitazone 0-3 serpin family E member 1 Homo sapiens 87-92 15990085-3 2005 In an endothelial cell line, Rosiglitazone (RG) and Pioglitazone (PG) inhibited induction of PAI-1 by TNFalpha. Rosiglitazone 29-42 serpin family E member 1 Homo sapiens 93-98 16957566-6 2006 Addition of rosiglitazone to metformin also reduced levels of plasminogen activator inhibitor-1 antigen and activity, C-reactive protein, von Willebrand factor and fibrinogen compared with addition of glyburide. Rosiglitazone 12-25 serpin family E member 1 Homo sapiens 62-95 17087601-6 2007 Rosiglitazone treatment improved diabetes compensation, significantly reduced VCAM-1, PAI-1 and E-selectin concentrations and increased adiponectin levels, while it did not affect serum resistin concentrations. Rosiglitazone 0-13 serpin family E member 1 Homo sapiens 86-91 12615670-0 2003 Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Rosiglitazone 83-96 serpin family E member 1 Homo sapiens 21-26 15899724-11 2005 Significant improvement in plasminogen activator inhibitor (PAI)-1 was present in the rosiglitazone group after 9 months (p<0.05), and significant PAI-1 improvement was observed in the glimepiride and rosiglitazone groups after 12 months (p<0.05 and p<0.01, respectively). Rosiglitazone 86-99 serpin family E member 1 Homo sapiens 27-66 12940867-10 2003 In contrast, insulin + RSG (10-8 m) reduced PAI-1 production relative to insulin alone (***p < 0.001), whilst RSG alone reduced PAI-1 protein secretion in a concentration-dependent manner (RSG at 10-10 m: 50.4 +/- 2.87 ng/ml downward arrow ***; RSG at 10-5 m: 30.3 +/- 2.0 ng/ml downward arrow ***; p < 0.001). Rosiglitazone 113-116 serpin family E member 1 Homo sapiens 131-136 12940867-14 2003 Therefore, RSG"s effects on PAI-1 production in adipose tissue may contribute to the fall in circulating PAI-1 levels observed in patients receiving RSG therapy. Rosiglitazone 11-14 serpin family E member 1 Homo sapiens 28-33 12940867-14 2003 Therefore, RSG"s effects on PAI-1 production in adipose tissue may contribute to the fall in circulating PAI-1 levels observed in patients receiving RSG therapy. Rosiglitazone 11-14 serpin family E member 1 Homo sapiens 105-110 12940867-14 2003 Therefore, RSG"s effects on PAI-1 production in adipose tissue may contribute to the fall in circulating PAI-1 levels observed in patients receiving RSG therapy. Rosiglitazone 149-152 serpin family E member 1 Homo sapiens 28-33 12940867-14 2003 Therefore, RSG"s effects on PAI-1 production in adipose tissue may contribute to the fall in circulating PAI-1 levels observed in patients receiving RSG therapy. Rosiglitazone 149-152 serpin family E member 1 Homo sapiens 105-110 12661797-4 2003 As reviewed below, rosiglitazone has a beneficial impact on a number of factors associated with insulin resistance and CVD, including microalbuminuria, hypertension, dyslipidaemia, visceral fat, elevated plasminogen activator inhibitor-1 levels and increased concentrations of C-reactive protein. Rosiglitazone 19-32 serpin family E member 1 Homo sapiens 204-237 15045127-3 2004 Troglitazone, rosiglitazone, and ciglitazone significantly reduced PAI-1 protein expression in human preadipocytes under basal conditions and after stimulation of the cells with TGF-beta. Rosiglitazone 14-27 serpin family E member 1 Homo sapiens 67-72 12940867-0 2003 Rosiglitazone inhibits the insulin-mediated increase in PAI-1 secretion in human abdominal subcutaneous adipocytes. Rosiglitazone 0-13 serpin family E member 1 Homo sapiens 56-61 12940867-1 2003 OBJECTIVE: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Rosiglitazone 108-121 serpin family E member 1 Homo sapiens 150-183 12940867-1 2003 OBJECTIVE: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Rosiglitazone 108-121 serpin family E member 1 Homo sapiens 185-190 12940867-1 2003 OBJECTIVE: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Rosiglitazone 123-126 serpin family E member 1 Homo sapiens 150-183 12940867-1 2003 OBJECTIVE: The aim of this study was to investigate the effect of insulin and an insulin-sensitizing agent, rosiglitazone (RSG), on the production of plasminogen-activator inhibitor-1 (PAI-1) in isolated subcutaneous abdominal adipocytes. Rosiglitazone 123-126 serpin family E member 1 Homo sapiens 185-190 12940867-10 2003 In contrast, insulin + RSG (10-8 m) reduced PAI-1 production relative to insulin alone (***p < 0.001), whilst RSG alone reduced PAI-1 protein secretion in a concentration-dependent manner (RSG at 10-10 m: 50.4 +/- 2.87 ng/ml downward arrow ***; RSG at 10-5 m: 30.3 +/- 2.0 ng/ml downward arrow ***; p < 0.001). Rosiglitazone 23-26 serpin family E member 1 Homo sapiens 44-49 12940867-10 2003 In contrast, insulin + RSG (10-8 m) reduced PAI-1 production relative to insulin alone (***p < 0.001), whilst RSG alone reduced PAI-1 protein secretion in a concentration-dependent manner (RSG at 10-10 m: 50.4 +/- 2.87 ng/ml downward arrow ***; RSG at 10-5 m: 30.3 +/- 2.0 ng/ml downward arrow ***; p < 0.001). Rosiglitazone 113-116 serpin family E member 1 Homo sapiens 131-136 12957323-10 2003 Rosiglitazone, an agent with insulin-sensitizing properties, decreases PAI-1 and CRP levels. Rosiglitazone 0-13 serpin family E member 1 Homo sapiens 71-76 12615670-3 2003 plasma PAI-1 antigen concentrations are related to liver fat content (LFAT) independently of the size of other fat depots and (2) rosiglitazone decreases PAI-1 and LFAT in these patients. Rosiglitazone 130-143 serpin family E member 1 Homo sapiens 154-159 12615670-10 2003 Rosiglitazone decreased LFAT, serum insulin, and plasma PAI-1 and increased serum triglycerides but had no effect on intra-abdominal or subcutaneous fat mass or PAI-1 mRNA. Rosiglitazone 0-13 serpin family E member 1 Homo sapiens 56-61 12615670-12 2003 Rosiglitazone decreases LFAT, serum insulin, and plasma PAI-1 without changing the size of other fat depots or PAI-1 mRNA in subcutaneous fat. Rosiglitazone 0-13 serpin family E member 1 Homo sapiens 56-61 12037506-3 2002 In type 2 diabetic patients, rosiglitazone and/or other thiazolidinediones have shown beneficial effects on blood pressure, arterial wall, vasomotricity, PAI-1 levels and urinary albumin excretion. Rosiglitazone 29-42 serpin family E member 1 Homo sapiens 154-159 26734075-10 2016 Only rosiglitazone decreased Homa beta, PAI-1 activity, CRP, fibrinogen, TGFbeta, FFA and triglyceride levels. Rosiglitazone 5-18 serpin family E member 1 Homo sapiens 40-45 11887975-3 2001 OBJECTIVES: To evaluate whether hyperglycaemia in two lean patients with primary severe insulin resistance due to insulin receptor (IR) mutations and diabetes mellitus could be reduced by supplement of rosiglitazone for 180 days and secondary, to evaluate the effects on plasma NEFA, TG, Apo B, PAI-1 and serum insulin. Rosiglitazone 202-215 serpin family E member 1 Homo sapiens 295-300 22415569-8 2012 Rosiglitazone, but not placebo, significantly reduced leukocyte count and plasma levels of matrix metalloproteinase-9 and inhibited the elevation of plasma levels of plasminogen activator inhibitor-1 and tissue plasminogen activator (P < 0.05 for all). Rosiglitazone 0-13 serpin family E member 1 Homo sapiens 166-199 25897968-8 2015 Subgroup analyses of PAI-1, vWF% and fibrinogen in terms of trial drugs showed significant reductions for rosiglitazone (all p valuses< 0.05), but not pioglitazone treatment. Rosiglitazone 106-119 serpin family E member 1 Homo sapiens 21-26 24793974-13 2014 The SB203580 or rosiglitazone pretreatment showed an attenuation of glucose-induced down-regulation of uPA and PAI-1. Rosiglitazone 16-29 serpin family E member 1 Homo sapiens 111-116